We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03347903
Recruitment Status : Completed
First Posted : November 20, 2017
Last Update Posted : November 21, 2017
Sponsor:
Information provided by (Responsible Party):

November 15, 2017
November 20, 2017
November 21, 2017
January 1, 2014
May 30, 2017   (Final data collection date for primary outcome measure)
Prevalence of Jackhammer esophagus in patients referred with symptoms of gastroesophageal reflux disease [ Time Frame: January 2014- May 2017 ]
All patients that are referred to our center with symptoms of gastroesophageal reflux disease routinely undergo high-resolution manometry. We assess how many patients are diagnosed with Jackhammer esophagus
Same as current
Complete list of historical versions of study NCT03347903 on ClinicalTrials.gov Archive Site
  • Symptom perception [ Time Frame: January 2014- May 2017 ]
    We assess which symptoms are perceived by the patients diagnosed with Jackhammer esophagus. All data are observed during an interview at the high-resolution manometry
  • Prevalence of gastroesophageal reflux disease in patients with Jackhammer esophagus [ Time Frame: Januar 2014- May 2017 ]
    All patients that are referred to our center are evaluated for gastroesophageal reflux disease. We assess the prevalence of gastroesophageal reflux disease in patients with Jackhammer esophagus diagnosed by ambulatory pH monitoring.
Same as current
Not Provided
Not Provided
 
Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease
Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is involved in the development of esophageal motility disorders like Jackhammer esophagus (JE), a novel hypercontractile condition that was associated with progression to achalasia and limited outcomes following surgical anti-reflux therapy.

This trial was designed to assess the prevalence and characteristics of JE in patients with typical symptoms of GERD and responsiveness to PPI therapy.

Jackhammer esophagus is a novel hypercontractile esophageal disorder. The investigators assess the prevalence and clinical characteristics of patients diagnosed with this disorder out of a collective of patients that are referred with symptoms of gastroesphageal reflux disease and respond to PPI. This is an observational trial.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
All patients that are referred to our center undergo esophageal high-resolution manometry and ambulatory pH monitoring for screening of gastroesophageal reflux disease and motility disorders. We assess the data that are prospectively obtained. Patients do not have to undergo any interventions.
Esophageal Motility Disorders
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
May 30, 2017
May 30, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with symptoms of gastroesophageal reflux disease and diagnosis of Jackhammer esophagus

Exclusion Criteria:

  • patients not willing to participate data or undergo screening for gastroesophageal reflux disease
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT03347903
1164/2017
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Dr. Ivan Kristo, Medical University of Vienna
Medical University of Vienna
Not Provided
Principal Investigator: Sebastian Schoppmann, MD Vice Chair of Department of General Surgery
Medical University of Vienna
November 2017